Govedarović Nenad, Vukičević Tomislav
Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:123-8. doi: 10.2298/sarh11s2123g.
Myeloma multiplex is a malignant blood disease in which monoclonal expansion of malignant plasma cells occurs, together with hyperproduction of monoclonal protein, as well as impairment of normal haematopoiesis. Specific features of myeloma include bone destruction, renal failure and immunologic deficiency which decreases the overall quality of the patient's life. Thus, prevention and supportive therapy of skeletal disease, anaemia, pain, nausea, infection and hypercalcemia, represent the essential part of therapy in myeloma patients. Improvements achieved in the specific haematological treatment including supportive measures of complications of multiple myeloma, previously defined as incurable malignant disease, results in the improvement of the overall survival and the quality of life of these patients, thus qualifing multiple myeloma into a chronic condition.
多发性骨髓瘤是一种恶性血液病，其中恶性浆细胞发生单克隆增殖，同时单克隆蛋白过度产生，以及正常造血功能受损。骨髓瘤的具体特征包括骨质破坏、肾衰竭和免疫缺陷，这些会降低患者的整体生活质量。因此，预防和支持治疗骨骼疾病、贫血、疼痛、恶心、感染和高钙血症，是骨髓瘤患者治疗的重要组成部分。在特定血液学治疗方面取得的进展，包括对曾被定义为无法治愈的恶性疾病——多发性骨髓瘤并发症的支持性措施，使得这些患者的总生存期和生活质量得到改善，从而将多发性骨髓瘤归类为一种慢性病。
